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ABSTRACT
Schumacher, Alexandra Nicole. Validation of the Six-Minute Walk Test for Predicting
Peak Oxygen Consumption in Cancer Survivors. Unpublished Master of Science
Thesis, University of Northern Colorado, 2017.

Exercise improves cardiovascular function in cancer survivors (CS) suffering
from treatment-related toxicities, such as decreased peak oxygen consumption (VO2peak).
Establishing valid assessment protocols that determine VO2peak are essential for
developing individualized exercise prescriptions for cancer rehabilitation programs. The
University of Northern Colorado Cancer Rehabilitation Institute (UNCCRI) has
developed a valid cancer-specific VO2peak treadmill protocol to address this need. The
six-minute walk test (6MWT) is an exercise assessment used in many populations with
chronic disease to predict VO2peak but it is not clear whether this test accurately assesses
VO2peak in CS. The 6MWT is simple, inexpensive, and representative of daily living
activities. Purpose: To assess the validity of predicted VO2peak from the 6MWT
compared to the UNCCRI treadmill protocol in CS. Methods: 128 CS completed a
UNCCRI treadmill protocol and a 6MWT one week apart in randomized order to obtain
VO2peak (mL/kg/min). VO2peak values from the UNCCRI treadmill protocol were
compared against four common 6MWT VO2peak prediction equations. Results: All four
6MWT prediction equations significantly (p < 0.001) underestimated VO2peak with
predicted values ranging from 8.3 ± 3.8 to18.9 ± 3.0 mL/kg/min, while the UNCCRI
treadmill protocol yielded a much higher value of 24.7 ± 7.4. A positive strong
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correlation occurred between the UNCCRI treadmill protocol and one of the 6MWT
prediction equations (r = 0.83) and a moderately strong correlation occurred between the
UNCCRI treadmill protocol and another 6MWT equation (r = 0.70). Maximum heart
rates were significantly higher (p < 0.001) during the UNCCRI treadmill protocol
compared to the 6MWT (150 ± 21 bpm vs. 109 ± 21 bpm). Conclusion: These findings
suggest that the 6MWT is not a valid test for predicting VO2peak in CS due to its
underestimation when using all four equations. The UNCCRI treadmill protocol is a
more accurate means of assessing VO2peak in CS in order to correctly prescribe an
individualized exercise rehabilitation program.
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CHAPTER I

INTRODUCTION

The number of people living beyond a cancer diagnosis in the United States is
expected to rise to almost 19 million by 2024 (National Cancer Institute [NCI], 2016).
Although cancer accounts for nearly one in four deaths, death rates are continuing to
decline (NCI, 2016). Due to an increase in the number of cancer survivors (CS), cancer
is being viewed as a chronic illness requiring long term management and rehabilitation
(Spence, Heesch, & Brown, 2010). Cancer and its treatment can result in significant
toxic side effects that impact the cardiopulmonary system. Cardiotoxicity from
chemotherapy leads to decreases in cardiac output and aerobic capacity, resulting in
complications such as cardiomyopathy and left ventricular dysfunction (Carver et al.,
2007; Dy & Adjei, 2013; Eschenhagen et al., 2011; Yusuf, Razeghi, & Yeh, 2008).
Treatment toxicities can be amplified in elderly CS because gerontological populations
are more inclined to have increased rates of heart failure, coronary artery disease,
arrhythmias, and left ventricular dysfunction (Sawhney, Sehl, & Naeim, 2005). Many
cancer rehabilitation programs exist to combat the physiological deficits from treatment
through exercise interventions and are primarily focused on improving quality of life.
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Exercise interventions are feasible in CS and a prescriptive plan leads to
physiological improvement in areas such as muscular strength and aerobic capacity
(Spence et al., 2010). Peak oxygen uptake (VO2peak) is a measure of aerobic fitness that
is consistently lower in CS compared to age-matched healthy individuals, and is often
directly affected by the cytotoxic therapies that adversely impact the organ systems
involved in exercise (Jones et al., 2011). Exercise rehabilitation in CS has a positive
impact on cardiorespiratory function and consequently increases VO2peak. The results of
a VO2peak assessment can provide clinicians with baseline information needed to
prescribe the correct intensity of exercise as well as the correct progression throughout a
cancer rehabilitation program. Establishing valid assessment protocols that determine
VO2peak are essential for developing individualized exercise prescriptions for cancer
rehabilitation programs.
Maximal cardiopulmonary exercise testing (CPET) is considered the gold
standard for measuring VO2peak, but it can be expensive, time consuming, and requires
trained medical personnel to be present. CPET has been found to be safe and feasible for
those with advanced cancer (Jones et al., 2007) but some CPET protocols may be too
difficult for CS to complete while others provide inaccurate results (Shackelford, Brown,
Peterson, Schaffer, & Hayward, 2015). The University of Northern Colorado Cancer
Rehabilitation Institute (UNCCRI) developed an accurate and valid treadmill protocol to
estimate VO2peak specifically for the cancer population. The UNCCRI treadmill protocol
has decreased grades and speeds to accommodate virtually any pulmonary,
musculoskeletal, and cardiovascular dysfunctions caused by cancer treatments
(Shackelford et al., 2015). The UNCCRI treadmill protocol has more manageable
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increases in intensity and provides a useful VO2peak value that allows for a complete an
accurate exercise prescription (Shackelford et al., 2015).
The six-minute walk test (6MWT) is a submaximal exercise assessment used in
many populations with chronic disease to predict VO2peak (American Thoracic Society,
2002; Cahalin, Mathier, Semigran, Dec, & DiSalvo, 1996; Ross, Murthy, Wollak, &
Jackson, 2010; Zugck et al., 2000), but it is not clear whether this test accurately assesses
VO2peak in CS. The 6MWT is favored in clinical populations because it is simple,
inexpensive, and representative of activities of daily living.
Statement of Purpose
The purpose of this study is to evaluate the validity of the 6MWT for predicting
VO2peak compared to the UNCCRI treadmill protocol in CS.
Research Hypotheses
H1

The VO2peak predicted from the 6MWT equations will be significantly
lower than the VO2peak obtained from the UNCCRI treadmill protocol.

H2

The predicted VO2peak from the multivariate 6MWT equations will have a
higher correlation with the UNCCRI treadmill protocol VO2peak.
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CHAPTER II

REVIEW OF LITERATURE
Introduction
Cancer is a disease characterized by abnormal cell growth and division. There are
over a hundred different types of cancer, the most common being breast, lung and
bronchus, prostate, and colorectal (NCI, 2016). Over 1.6 million new cases of cancer
were predicted to be diagnosed in 2016 within the United States (ACS, 2016). In the
U.S., the lifetime risk of developing cancer is 42% for men and 38% for women (ACS,
2016). Even though death rates for the most common cancers are declining, cancer is the
leading cause of death worldwide and accounts for nearly 1 of every 4 deaths (NCI,
2016). The number of people living beyond a cancer diagnosis in the U.S. is suspected to
rise to almost 19 million by 2024 compared to 14.5 million in 2014 (NCI, 2016). As the
number of cancer survivors (CS) continues to increase, it is imperative that cancer
rehabilitation programs utilize proper assessment and training techniques. Exercise
opposes the physiological decline in CS and an individual exercise prescription
formulated from an initial assessment can help improve quality of life after a cancer
diagnoses.

5
Cardiopulmonary Toxicity in Cancer Survivors
Cancer and its therapies for cancer can result in detrimental side effects that may
significantly impact the cardiopulmonary system. The most common cancer treatments
include surgery, chemotherapy, and radiation therapy. Chemotherapy drugs are
especially known for eliciting severe toxic effects to the different physiological systems.
Anthracyclines are one common class of chemotherapy agents that result in direct DNA
damage through intercalation, interference with DNA repair through the inhibition of
topoisomerase II, and the formation of free radicals. This damage and disruption leads to
the eventual apoptosis of cells (Arola et al., 2000; Monsuez, Charniot, Vignat, & Artigou,
2010). Radiation therapy leads to similar DNA damage and cell death. Unfortunately,
these treatments do not specifically target cancer cells and are concurrently toxic to
healthy tissues resulting in detrimental symptoms (Eschenhagen et al., 2011).
The toxic effects of chemotherapy have been extensively studied in relation to
cardiac function. Common cardiotoxicities of chemotherapy include arrhythmias, left
ventricular dysfunction, myocardial ischemia, and cardiomyopathy with or without
congestive heart failure (Carver et al., 2007; Dy & Adjei, 2013; Eschenhagen et al., 2011;
Yusuf et al., 2008). Cardiac damage from radiation therapy can lead to coronary artery
disease (CAD), valve diseases, chronic pericardial disease, arrhythmias, conduction
disturbances, cardiomyopathy, and carotid artery stenosis (Carver et al., 2007; DeSantis
et al., 2014). Thoracic radiotherapy can also damage the vascular network, resulting in
reduced capillarization, decreased blood perfusion, anemia, and interstitial edema
(Schneider, Dennehy, & Carter, 2003). Deficiencies within the cardiovascular system of
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supplying oxygen and nutrients to the major organ systems of the body can significantly
reduce CS quality of daily living.
The pulmonary system is a key component in healthy cardiorespiratory function.
Radiotherapy to the chest often results in radiation pneumonitis, pulmonary fibrosis, and
decreased pulmonary function (Carver et al., 2007). These toxicities result in decreases
in total and vital lung capacity, compromising the efficiency of oxygen diffusion and
carbon dioxide removal (Schneider, Hsieh, Sprod, Carter, & Hayward, 2007). Adverse
effects from chemotherapy include interstitial injury with the impairment of alveolar
capillary membranes (Marulli et al., 2010). The incidence of radiation pneumonitis has
been found to be five times greater with the addition of chemotherapy (Parashar et al.,
2011). Palma et al. (2012) found that of those undergoing concurrent chemotherapy for
non-small cell lung cancer (NSCLC), 30% are symptomatic of pneumonitis, increasing
the rate of oxygen dependence. The highest risk of radiation pneumonitis (>50%) occurs
in CS greater than 65 years due to the likelihood of comorbid conditions (Palma et al.,
2012; Parashar et al., 2011). A decrease in pulmonary reserve from these treatments may
prevent patients from undergoing potential curative surgery to remove cancer (Sawhney
et al., 2005). Surgery for tumor removal in the lungs can also impact lung function
adversely due to an increase in scar tissue (DeSantis et al., 2014).
Guidelines for Physical Activity in Cancer Survivors
Physical activity improves physiological functioning in healthy individuals and
those managing chronic disease conditions (Stevinson, Lawlor, & Fox, 2004). Physical
activity of any kind can result in higher physical functioning, but an exercise prescription
including 20-30 min of moderate intensity activity most days of the week was found to
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have the greatest benefit for functional capacity in elderly (Brach, Simonsick,
Kritchevsky, Yaffe, & Newman, 2004). With advancements in early detection and
improved treatments, cancer is being viewed more often as a chronic illness requiring
long term management and rehabilitation (Spence et al., 2010). Cancer treatments may
lead to prolonged periods of inactivity which often lingers after treatment has ended
(Burnham & Wilcox, 2002; Doyle et al., 2006; Midtgaard et al., 2013). In CS, physical
activity not only helps to manage any co-occurring chronic conditions, but helps prevent
reoccurring cancer and secondary cancers (Doyle et al., 2006). In women with breast
cancer who followed the U.S. guidelines for physical activity, there was found to be a 2640% lower risk of death from reoccurrence (Holmes, 2005). The area of physical
rehabilitation utilizing an exercise prescription with aerobic and resistance components
for CS is a growing field gaining plenty of momentum due to the support from research.
Primary evidence from a systematic review citing 33 controlled trials concluded that
physical activity through exercise interventions in CS leads to moderate increases in
physical function, further resulting in increased activities of daily living (Stevinson et al.,
2004). A similar systematic review of 10 studies with exercise interventions in CS
concluded that exercise is feasible and provides a physiological improvement in several
areas including strength and aerobic capacity during cancer rehabilitation (Spence et al.,
2010). Recently, it was concluded that exercise training may help increase exercise
capacity for people following lung resection in those diagnosed NSCLC (Cavalheri,
Tahirah, Nonoyama, Jenkins, & Hill, 2014).
In 2010, the American College of Sports Medicine (ACSM) hosted a roundtable
discussion with several professionals in the cancer rehabilitation field. They concluded
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that exercise training during and after cancer treatment is safe and results in
improvements in physical functioning, quality of life, and cancer related fatigue (Schmitz
et al., 2010). Physical activity guidelines have been established to accommodate other
chronic health conditions, and the ACSM discussion determined the current guidelines of
150 minutes per week of moderate activity or 75 minutes per week of vigorous activity,
are appropriate for CS (Schmitz et al., 2010). However, it was cautioned that exercise
interventions in CS should be individualized and monitored by professionals in the field
due to possible differences in treatments, pre-aerobic fitness, comorbidities, responses to
treatment, and any other adverse effects (Schmitz et al., 2010; Schneider et al., 2007).
Maximum and Peak Oxygen Consumption
VO2max is an assessment of cardiorespiratory fitness (CRF) measuring the ability
of the cardiorespiratory system to utilize oxygen through intake and transport to skeletal
muscle for ATP synthesis. CRF is a powerful predictor of mortality in healthy
populations. VO2max is the product of maximum cardiac output and maximum arterialmixed venous oxygen difference, measured in absolute (L/min) or relative (mL/kg/min)
terms. VO2max declines with inactivity, age, and disease conditions, and is an important
measure to monitor physiological status after an intervention. A meta-analysis of 4884
subjects showed that there is a decline in VO2max of approximately 10 mL/kg/min per
decade (Fitzgerald, Tanaka, Tran, & Seals, 1997; Lakoski, Eves, Douglas, & Jones,
2012).
A true measure of VO2max requires that an individual reach a Respiratory
Exchange Ratio (RER) greater than 1.15, blood lactate levels greater than 8 mmol/L, and
reach a plateau in oxygen consumption during maximal exercise testing measured by gas
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analysis (ACSM, 2013). When criteria are not reached, it is considered to be a
measurement of peak oxygen consumption. VO2peak is defined as the highest oxygen
consumption measured during the last 30 seconds of a symptom limited exercise test and
is likely a valid measure of VO2max during maximum effort (Day, Rossiter, Coats,
Skasick, & Whipp, 2003; May et al., 2010; Zugck et al., 2000). VO2peak also measures
the ability of the cardiorespiratory system to deliver oxygen to skeletal muscle and the
efficiency of the muscle to utilize the oxygen, however it is more reproducible than
VO2max (Day et al., 2003). In a study of 26 control subjects and 55 subjects with CAD,
23% did not reach a plateau during VO2max testing (Eldridge, Ramsey-Green, Hossack,
1986), and more recently only 17% of 71 subjects who exercised to their maximum limit
of tolerance reached a plateau during testing (Day et al., 2003). Cardiac responses
between subjects who did or did not reach a plateau did not differ, concluding that
VO2peak is a valid measure of maximum cardiac capacity (Eldridge et al., 1986). VO2peak
has gained acceptance as a measure of VO2max in clinical populations (Cote, Pinto-Plata,
Kasprzyk, Dordelly, & Celli, 2007).
VO2peak is the measure often used in CS to assess CRF (May et al., 2010; Schmidt,
Vogt, Thiel, Jager, & Banzer, 2013) and greater CRF is associated with a reduced risk of
dying from cancer (Doyle et al., 2006; Jones et al., 2011; Klika, Callahan, & Drum,
2009; Peel et al., 2009). VO2peak is consistently lower in CS, often directly a result of the
cytotoxic therapies that adversely impact the organ systems involved in exercise (Jones et
al., 2011). Smoot, Johnson, Duda, Krasnoff, & Dodd (2012) found the mean VO2peak in
120 breast CS to be 25 ml/kg/min, which falls below the 30th percentile for published
healthy norms. Another study found the mean VO2peak value for 346 pre-surgical patients
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with NSCLC to be 16 ± 0.4 mL/kg/min, equivalent to only 36% of sex and age matched
individuals (Loewen et al., 2007). Burnett, Kluding, Porter, Fabian, & Klemp (2013)
found that 77% of their study participants with breast cancer had a VO2max below the 20th
percentile for norms.
Exercise rehabilitation in CS has proven to have a positive impact on
cardiorespiratory function and thus increases VO2peak. A recent study found a significant
improvement in VO2peak of over 3 mL/kg/min after a 3-month exercise intervention
(Repka et al., 2014). A meta-analysis of pooled data from six different exercise
intervention studies in CS (N=571) concluded that there was a significant increase in
VO2peak of almost 3 mL/kg/min, compared with a decrease in VO2peak of -1 mL/kg/min in
those CS who didn’t receive an exercise intervention (Jones et al., 2011). In a different
intervention study it was concluded that physical activity was able to blunt a decline in
VO2max by 8% (Courneya et al., 2007), and similar results have been observed by others
(Midtgaard et al., 2013; Quist et al., 2006; Schneider et al., 2007). Contrary to the
previous results, 37 CS of multiple myeloma underwent a three-month exercise
intervention with no significant change in oxygen consumption (p = 0.057) (Groeneveldt
et al., 2013). There was a positive improvement in VO2peak, but the result was not
significant. This was likely due to the intensity of the intervention being less than (50%
HRR) other similar studies (Groeneveldt et al., 2013).
Exercise Testing in Cancer Survivors
Cardiopulmonary Exercise Testing
Maximal cardiopulmonary exercise testing (CPET) is considered the “gold
standard” for measuring VO2max (Burnett et al., 2013; Turner, Eastwood, Cecins, Hillman
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& Jenkins, 2004). CPET requires gas analysis with a metabolic cart, is expensive, time
consuming, and requires trained medical personnel to be present, especially in clinical
populations. The American Thoracic Society (ATS) defines formal CPET as a test to
provide a global assessment of the exercise response and an objective determination of
functional capacity or impairment. It can determine the appropriate intensity needed to
perform prolonged exercise and define underlying pathophysiologic mechanisms (ATS,
2002).
During CPET testing, workload is increased progressively until symptoms force
discontinuation of the test (Cote et al., 2007). CPET can be conducted using gas analysis
during various treadmill, step, and cycle ergometer protocols. Validated treadmill
protocols are safe, reliable, and the ACSM provides accurate prediction equations to
estimate VO2max clinically using the last stage of completion when gas analysis is not
available (ACSM, 2013). VO2max has been shown to be 5-10% higher when a treadmill
protocol is used compared with a cycle ergometer test protocol (Bruce, Kusumi, &
Hosmer, 1973; Cahalin et al., 1996; Jones et al., 2007).
Exercise performance can be greatly reduced in patients with heart failure and
similar diseases affecting cardiopulmonary systems (Zugck et al., 2000). CPET is a
powerful tool that can provide information on the nature of cardiorespiratory response to
exercise in chronic disease populations (Cote et al., 2007). Ramp protocols are
commonly utilized in elderly or clinical populations with more limited capacity. These
protocols can be less intimidating because they increase speed and grade continuously to
reach peak cardiovascular responses (Bader, Maguire, & Balady, 1999). The lower the
workload increments, the less likely that tests will be terminated due to other factors
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other than maximum cardiopulmonary responses, thus reducing errors of estimation for
VO2max (Shackelford et al., 2015). Reliable, accurate, and valid CPET are of utmost
importance in clinical populations in order to optimize rehabilitation programs, prescribe
individual training intensities, and to improve quality of life for patients (De Backer et
al., 2007; Gayda, Temfemo, Choquet, & Ahmaidi, 2004).
Promising research has led to an increase in cancer rehabilitation programs, yet
there are few standards for assessing exercise capacity in CS (Stubblefield, 2013).
Clinics assessing CS may choose to use a submaximal test due to impaired balance and
coordination even when CPET has been found to be safe and feasible for those with
advanced cancer (Jones et al., 2007; Klika et al., 2009). Like other healthy and chronic
disease populations, CPET in CS is very important for screening, exercise prescription
and determination of exercise capacity (Jones et al., 2007).
The University of Northern Colorado Cancer Rehabilitation Institute (UNCCRI)
has developed an accurate and valid treadmill protocol to estimate VO2peak in a cancer
specific population. CPET protocols for healthy or other populations may be too difficult
for CS to complete safely, therefore the UNCCRI protocol has decreased grades and
speeds to accommodate any pulmonary, musculoskeletal, and cardiovascular
dysfunctions caused by cancer treatments (Shackelford et al., 2015). Both CS and
apparently healthy subjects performed a Bruce treadmill protocol and the UNCCRI
treadmill protocol with and without gas analysis. The correlation for all participants
between VO2peak with and without gas analysis for the UNCCRI protocol was r = 0.90.
These results suggest that ACSM’s walking/running equations are valid for determining
VO2peak in CS and gas analysis is not required with this protocol. No CS had any adverse
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effects when completing any of the protocols, indicating CS can complete a VO2peak test
safely. In CS, heart rates during the Bruce protocol were significantly lower at
termination than the UNCCRI protocol. CS often terminated the Bruce protocol due
more to muscle fatigue than actual cardiorespiratory effects. The Bruce has been shown
to overestimate VO2peak and thus will yield inaccurate prescriptions that could hinder CS
if too intense (Bader et al., 1999; Shackelford et al., 2015). The UNCCRI protocol is
more appropriate due to smaller work increments, which yield a more accurate
relationship between oxygen supply and demand (Jones et al., 2007; Shackelford et al.,
2015). Establishing accurate VO2peak values for CS is the first step in the process of
designing and implementing an accurate exercise prescription.
There are several instances why maximal testing may not be performed. CPET
may not be widely available to clinics outside of hospitals due to expense and the
availability of medical personnel, and may be contraindicated in severely limited
populations (Burnett et al., 2013; Cahalin et al., 1996; Guyatt et al., 1985). It may be
perceived that CPET places an unwarranted burden on patients due to the test being
exhaustive, thus bringing safety into question. In patients with chronic obstructive
pulmonary disease (COPD), it was found that symptoms interfere long before a possible
VO2peak could be achieved (Cote et al., 2007). Studies have reported that the gas analysis
apparatus may be extremely uncomfortable for patients and could yield inaccurate results
(Shackelford et al, 2015; Zugck et al., 2000). CPET may also be impractical for
populations who need frequent assessments (Green, Watts, Rankin, Wong, & Driscoll,
2001).
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For these reasons, submaximal testing is often chosen in lieu of a maximal test in
clinical environments without access to formal CPET. Submaximal testing allows for a
measure of sustainable cardiovascular response to exercise capacity safely without
maximizing heart rate (Burnett et al., 2013). Submaximal testing at 85% age predicted
heart rate max shows a strong correlation (r = 0.89) with predicted VO2max (Burnett et al.,
2013). May et al. (2010) concluded that there was not a significant difference (p = 0.1)
between VO2max measured from CPET versus VO2max estimated from submaximal
workload and a heart rate response greater than 140 bpm could serve as an alternative to
maximal testing. However, it has been demonstrated that heart rate can vary
substantially during submaximal workloads and it is important to assess patients based on
individual needs and capacity (De Backer et al., 2007). Therefore, CPET is still the
preferred protocol for initial assessments, particularly for prescribing an accurate exercise
prescription during rehabilitation. However, submaximal testing allows for more
frequent assessments to monitor clinical progress.
The Six-Minute Walk Test
One of the most utilized submaximal tests in clinical populations is the six-minute
walk test (6MWT). The 6MWT was first developed as a twelve-minute walk test but
was further adapted to six minutes for more limited pulmonary populations. It has since
been used in cardiac populations and rehabilitation settings (Enright, 2003; Guyatt et al.,
1985). The 6MWT is a quick, inexpensive measure of physical function. It can be
performed with frail, elderly, and severely limited patients (Enright & Sherrill, 1998;
Guyatt et al., 1985). It is favored in clinical populations because it is less expensive,
safe, and easy to administer. A walking test is also considered to be more reflective of
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daily living activities in these clinical populations. A protocol for conducting the 6MWT
has been standardized by the ATS. The test has high intra class correlation values greater
than 0.80 and a practice test is not needed (Sciurba et al., 2003; Steffen, Hacker, &
Mollinger, 2002; Weiss, 2000; Zugck et al., 2000).
Research in chronic disease populations concludes that the walk test is a valid test
for monitoring exercise capacity in those with lower VO2peak. In patients with COPD,
interstitial lung disease, and pulmonary hypertension, VO2peak measured during the
6MWT is not significantly different than VO2peak during CPET (Blanco et al., 2010;
Fujino et al., 2015; Hill et al., 2012; Starobin et al., 2006; Turner et al., 2004). In elderly
subjects with CAD, VO2peak during the 6MWT was not significantly different than CPET
VO2peak (14.3 ± 2.9 vs 13.4 ± 2.7 mL/kg/min) (Gayda et al., 2004). Hill et al. (2012)
found no significant differences between VO2peak (p = 0.31) and peak heart rate (p = 0.58)
values when comparing the 6MWT, shuttle walk tests, and a cycle CPET in those with
moderate COPD. Similar findings have been observed in those with heart failure and
cardiomyopathy (Faggiano, D’Aloia, Gualeni, Brentana, & Cas, 2004; Gayda et al.,
2004; Zugck et al., 2000).
Lipkin, Scriven, Crake, & Poole-Wilson (1986) were the first to demonstrate a
curvilinear relationship between VO2peak and distance walked during the 6MWT. The
findings documented that for a VO2peak over 20 mL/kg/min determined by CPET,
distance walked on the test varied. Since then several studies have confirmed a moderate
to high positive correlational relationship between the 6MWT distance and VO2peak in
clinical populations (Cahalin et al., 1996; Faggiano, D’Aloia, Gualeni, Lavatelli, &
Giordano, 1997; Faggiano et al., 2004; Gayda et al., 2004; Guazzi, Dickstein, Vicenzi, &
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Arena, 2009; Zugck et al., 2000). Cahalin et al. (1996) developed several prediction
equations from this linear relationship with distance to predict VO2peak in patients with
heart failure. These prediction equations are based not only on distance, but also on
multivariate factors like height and weight to help reduce the variability seen in
individual subjects. Ross et al. (2010) reviewed several studies and determined a valid
equation to predict VO2peak from 1083 patients with diverse cardiopulmonary diagnoses.
Other studies concluded similar findings to Lipkin et al. (1986) that the test becomes less
sensitive with greater functional capacity (Deboeck, Muylem, Vachiery, & Naeije, 2014;
Fujino et al., 2015; Jehn et al., 2009; Schmidt et al., 2013;)
Given the compromised state of CS, clinics may opt for submaximal protocols
like the 6MWT. Kasymjanova et al. (2009) used the 6MWT to determine which patients
might have less adverse physiological effects during chemotherapy treatment. They
found that those who walked a distance greater than 400m would likely have less
physiological side effects from treatment. The researchers found that after two cycles of
chemotherapy, the six-minute walk distance significantly declined by more than 54m in
29% of the subjects. Over half of the patients dropped out of the study due to the
consequences of chemotherapy. To our knowledge, Schmidt et al. (2013) are the only
researchers to evaluate the 6MWT and its correlation with VO2peak in CS. They chose a
cycle CPET to determine VO2peak because it was considered safer and there was no need
for time consuming treadmill familiarization trials. They found the 6MWT to be reliable
as an assessment tool and found a correlation between distance and VO2peak to be
moderate (r = 0.67). The average distance walked was 594 ± 81 m and subjects walked
with an intensity averaging 86 ± 10% of their estimated heart rate maximum. The
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researchers concluded the 6MWT was a valid test for determining functional capacity,
but may not be sensitive enough to detect intervention related effects in patients with
early stage disease. To our knowledge no studies have considered the validity of
established VO2peak prediction equations in cancer survivors.
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CHAPTER III

METHODOLOGY
Subjects
A total of 128 subjects participated in this study. All participants were cancer
survivors (CS) enrolled in the University of Northern Colorado Cancer Rehabilitation
Institute’s (UNCCRI) program. Inclusion criteria for participants included 1) diagnosed
with cancer, 2) at least 18 years of age, and 3) no history of stroke, chronic respiratory
difficulties, or severe arterial hypertension (resting systolic blood pressure > 200 mmHg,
resting diastolic blood pressure > 110, or both). Participants were referred to UNCCRI
and their medical records were obtained from the referring oncologist or primary care
physician. Participants signed an informed consent upon entering the program at
UNCCRI agreeing to participate in research within the institute. From 2015-2016,
participants entering the UNCCRI program enrolled in and completed this study.
Existing clients already in the program were recruited via flyers within the clinic for
participation. Participants may have been receiving chemotherapy (N = 21), radiation
therapy (N = 3), a combination of chemotherapy and radiation (N = 8), or
immunotherapy (N = 3) during participation. Prior to participation, a detailed
explanation was given about the study protocols.
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Exclusion criteria for participants included 1) history of congestive heart failure,
2) history of myocardial infarction, 3) chronic lung disease, 4) asthma, 5) significant
ambulatory issues, 6) history of coughing up blood, 7) fainting, and 8) epilepsy.
Safety was ensured by having trained Cancer Exercise Specialists (CES) supervising each
protocol. The protocols used in the study were approved by the University of Northern
Colorado’s Institutional Review Board (see Appendix B).
Experimental Design
The purpose of this study was to assess the validity of predicted VO2peak from the
6MWT compared to the validated UNCCRI treadmill protocol in CS. Participants
underwent a thorough initial interview and physician clearance to assure they could
complete VO2peak testing. Participants who qualified for the study completed one
UNCCRI treadmill protocol and one 6MWT one week apart in randomized order.
University of Northern Colorado Cancer Rehabilitation
Institute Treadmill Protocol
The UNCCRI treadmill protocol appears in detail in Table 1 and in Appendix C.
There are 21 total stages, each stage lasts a duration of one minute. Stage 0 starts at 1
mph and a 0% incline. Speed increased by no more than 0.5 miles per hour (mph)
between stages 0-6 and an incline of 2% was not observed until stage 4. Starting after
the 5th stage, speed was increased by 0.1 mph and grade increased by 1% after each
completed stage.
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Table 1
The University of Northern Colorado Cancer Rehabilitation Protocol
Stage

Speed Grade Time

0

1.0mph

0% 1 min

1

1.5mph

0% 1 min

2

2.0mph

0% 1 min

3

2.5mph

0% 1 min

4

2.5mph

2% 1 min

5

3.0mph

2% 1 min

6

3.3mph

3% 1 min

7

3.4mph

4% 1 min

8

3.5mph

5% 1 min

9

3.6mph

6% 1 min

10

3.7mph

7% 1 min

11

3.8mph

8% 1 min

12

3.9mph

9% 1 min

13

4.0mph

10% 1 min

14

4.1mph

11% 1 min

15

4.2mph

12% 1 min

16

4.3mph

13% 1 min

17

4.4mph

14% 1 min

18

4.5mph

15% 1 min

19

4.6mph

16% 1 min

20

4.7mph

17% 1 min

Cool Down

**

0%

***
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Resting blood pressure (BP), resting heart rate (HR), blood oxygen saturation
(SpO2), and body weight (kg) were measured before the treadmill test. Blood pressure
was measured manually by auscultation a sphygmomanometer and stethoscope, HR was
determined using a Polar® Heart Rate Monitor, SpO2 was measured using a Clinical
Guard® pulse oximeter, and body weight was measured by the InBody 770®. Three
Clinical Cancer Exercise Specialists conducted the treadmill test for safety. One CES
changed the grade and/or speed every minute dependent on the stage of the protocol, as
well as recorded vital information. One CES recorded BP every three minutes, while one
CES stood behind the participant during the duration of the protocol for spotting and
safety and to monitor any safety concerns.
Before each test participants were given the following instructions: 1) BP will be
taken every three minutes by a CES, 2) another CES will be recording HR and SpO2 and
changing speed and/or grade every minute, 3) a pulse oximeter will be placed on your
finger for the duration of the test to monitor oxygen saturation every minute, 4) a CES
will also stand behind you during the duration of the test for your safety and to ensure
proper placement on the treadmill belt, 5) we ask that you push yourself to maximum
exertion and although you may stop at any time, we would like you to reach the point
where you feel that you can’t physically continue, 6) we recommend that you do not use
the handrails unless you feel it is absolutely necessary, 7) you must choose to use or not
use the handrails for the entire protocol, 8) after maximal exertion a cool down phase at a
lower speed and grade will be initiated until vitals reach near-resting measures.
The test ended when the participant reached his or her perceived maximum
exertion or could not continue further. The test concluded when the participant verbally
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expressed they had reached their maximum rate of perceived exertion (RPE) using a
modified Borg RPE, or when the participant physically grabbed onto the handrails to
signal the end of the test. Once the participant indicated they had reached maximum
effort, the cool down phase was initiated. When the participant’s vitals were close to
resting vitals and the participant indicated that they felt safe to get off the treadmill, the
treadmill was stopped. Final vitals were recorded, including the maximum HR reached.
The duration of the test until maximum exertion and the final completed stage was also
recorded. HR and SpO2 continued to be recorded every minute, while BP and RPE
continued to be recorded every three minutes. When the participant vitals were close to
resting levels and the participant indicated that they felt safe to get off the treadmill, the
treadmill was stopped. Final vitals were recorded, including when the maximum HR
reached. The duration of the test until maximum exertion and the final completed stage
was also recorded.
The American College of Sports Medicine running and walking equations were
used to calculate VO2peak from the last completed stage of the protocol. If the participant
was walking at maximum exertion the following equation was used: VO2peak
(mL/kg/min) = (0.1 x S) + (1.8 x S x G) + 3.5. The variable S is the speed in meters/min
and G is the percentage of grade in decimal form. If the participant was running at
maximum exertion the following equation was used: VO2peak = (0.2 x S) + (0.9 x S x G)
+ 3.5. If the participant was using the handrails during the protocol the following
equation was used: VO2peak= 0.694 x [the ACSM walking/running value from above] +
3.33 (ACSM, 2013).
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The Six Minute Walk Test Protocol
The 6MWT protocol appears in Appendix D. The 6MWT was conducted under
the guidelines of the American Thoracic Society (ATS). The 6MWT took place in a
12.6-meter-long hallway at the UNCCRI. Prior to the 6MWT, participants performed a
pulmonary assessment using a MIR Spirolab III® portable desktop spirometer to assess
force vital capacity (FVC) and forced expiratory capacity (FEV1) of the lungs. Two
CES’s supervised the test to ensure participant safety.
At the beginning of the test each participant was given the following instructions:
1) walk up and down the hallway for six minutes, reaching the colored dot at each end of
the hallway, 2) try to walk as far as possible in that six-minute time frame, and 3) at any
time you can stop to rest or sit in one of the chairs, but we ask that you keep walking as
soon as you feel able. The participants were asked to walk alone unless gait imbalances
required them to have a CES near to assist them. At every minute, participants were told
the time remaining and a standard verbal encouragement such as “Great job” was given.
One CES kept track of the time on a stopwatch and placed a mark on the data collection
sheet every time the participant completed one length of the hallway. At the end of the
test, participants were asked to stop where they were and a CES marked on the wall
where they had stopped. The CES measured the partial distance the participant had
covered from the end of the hall to the spot on the wall with a meter stick. This value
was added to the total distance of lengths completed to ensure a precise measurement of
distance covered. At the end of the test HR, BP, RPE and SpO2 values were recorded
immediately by a CES.
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The distance and other variables were used to calculate predicted VO2peak from
four well established prediction equations: 1) VO2peak = 0.03 x distance (m) + 3.98
(Cahalin et al., 1996), 2) VO2peak = 0.02 x distance (m) – 0.191 x age (yrs) – 0.07 x
weight (kg) + 0.09 x height (cm) +0.26 x (RPP x 10^-3) + 2.45 (Cahalin et al., 1996), 3)
VO2peak = 0.02 + distance (m) - 0.14 x age (yrs) - 0.07 x weight (kg) + 0.03 x height (cm)
+ 0.23 x (RPP x 10^-3) + 0.10 x FEV1(L) – 1.19 x FVC (L) + 7.77 (Cahalin et al., 1996),
and 4) VO2peak = 4.948 + 0.023 x distance (m) (Ross et al., 2010).
Statistical Analysis
A power analysis was ran using the statistical program G-power (Version 3.1)
prior to the study to determine the appropriate sample size for significance. For both
protocols a repeated measures ANOVA was utilized to examine the differences in
VO2peak obtained by the UNCCRI treadmill protocol to against VO2peak values determined
by the four 6MWT prediction equations. It was assumed that 1) the dependent variable
of VO2peak was continuous, 2) the tests were matched pairs, 3) there were no significant
outliers, and 4) there was a normal distribution. Paired t-tests were utilized to test the
differences between HR and SBP between the UNCCRI protocol and the 6MWT
protocol. A Pearson r-correlation between the UNCCRI treadmill and 6MWT equations
1-4 to determine the strength of the relationship in VO2peak. Significance was set to p <
0.05. All statistics were derived using the Statistical Package for the Social Sciences
software package (SPSS, Chicago, IL).
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CHAPTER IV

MANUSCRIPT
Introduction
The number of people living beyond a cancer diagnosis in the United States is
expected to rise to almost 19 million by 2024 (NCI, 2016). Although cancer accounts for
nearly one in four deaths, death rates are continuing to decline (NCI, 2016). Due to an
increase in the number of cancer survivors (CS), cancer is being viewed as a chronic
illness requiring long term management and rehabilitation (Spence et al., 2010). Cancer
and its treatment can result in significant toxic side effects that impact the
cardiopulmonary system. Cardiotoxicity from chemotherapy leads to decreases in
cardiac output and aerobic capacity, resulting in complications such as cardiomyopathy
and left ventricular dysfunction (Carver et al., 2007; Dy & Adjei, 2013; Eschenhagen et
al., 2011; Yusuf et al., 2008;). Treatment toxicities can be amplified in elderly CS
because gerontological populations are more inclined to have increased rates of heart
failure, coronary artery disease, arrhythmias, and left ventricular dysfunction (Sawhney
et al., 2005). Many cancer rehabilitation programs exist to combat the physiological
deficits from treatment through exercise interventions and are primarily focused on
improving quality of life.
Exercise interventions are feasible in CS and a prescriptive plan leads to
physiological improvement in areas such as muscular strength and aerobic capacity
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(Spence et al., 2010). Peak oxygen uptake (VO2peak) is a measure of aerobic fitness that
is consistently lower in CS compared to age-matched healthy individuals, and is often
directly affected by the cytotoxic therapies that adversely impact the organ systems
involved in exercise (Jones et al., 2011). Exercise rehabilitation in CS has a positive
impact on cardiorespiratory function and consequently increases VO2peak. The results of
a VO2peak assessment can provide clinicians with baseline information needed to
prescribe the correct intensity of exercise as well as the correct progression throughout a
cancer rehabilitation program. Establishing valid assessment protocols that determine
VO2peak are essential for developing individualized exercise prescriptions for cancer
rehabilitation programs.
Maximal cardiopulmonary exercise testing (CPET) is considered the gold
standard for measuring VO2peak, but it can be expensive, time consuming, and requires
trained medical personnel to be present. CPET has been found to be safe and feasible for
those with advanced cancer (Jones et al., 2007) but some CPET protocols may be too
difficult for CS to complete while others provide inaccurate results (Shackelford et al.,
2015). The University of Northern Colorado Cancer Rehabilitation Institute (UNCCRI)
developed an accurate and valid treadmill protocol to estimate VO2peak specifically for the
cancer population. The UNCCRI treadmill protocol has decreased grades and speeds to
accommodate virtually any pulmonary, musculoskeletal, and cardiovascular dysfunctions
caused by cancer treatments (Shackelford et al., 2015). The UNCCRI treadmill protocol
has more manageable increases in intensity and provides a useful VO2peak value that
allows for a complete an accurate exercise prescription (Shackelford et al., 2015).
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The six-minute walk test (6MWT) is a submaximal exercise assessment used in
many populations with chronic disease to predict VO2peak (American Thoracic Society,
2002; Cahalin et al., 1996; Ross et al., 2010; Zugck et al., 2000), but it is not clear
whether this test accurately assesses VO2peak in CS. The 6MWT is favored in clinical
populations because it is simple, inexpensive, and representative of activities of daily
living. The purpose of this study was to evaluate the validity of the 6MWT for predicting
VO2peak compared to the UNCCRI treadmill protocol in CS.
Methods
Subjects
A total of 128 subjects participated in this study. All participants were CS
enrolled in UNCCRI’s cancer rehabilitation program. Participants were referred to
UNCCRI and their medical records were provided by their oncologist or primary care
physicians. Upon entering the program at UNCCRI, participants signed an informed
consent approved by the University of Northern Colorado’s Institutional Review Board
agreeing to participate in research within the institute. From 2015-2016, participants
entering the UNCCRI program enrolled in and completed this study. Existing clients
already in the program were recruited via flyers within the clinic for participation.
Participants were excluded if they had a history of congestive heart failure, myocardial
infarction, chronic lung disease, asthma, significant ambulatory issues, history of
coughing up blood, fainting, or epilepsy.
Experimental Design
Participants who qualified for the study completed one UNCCRI treadmill
protocol and one 6MWT one week apart in randomized order. Resting blood pressure
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(BP), resting heart rate (RHR), blood oxygen saturation (SpO2), height (cm), and body
weight (kg) were measured before each test. Blood pressure was measured manually by
auscultation, HR was determined using a Polar® Heart Rate Monitor, SpO2 was
measured using a Clinical Guard® pulse oximeter, height was measured by the BSM170
stadiometer, and body weight was measured by the InBody 770®. Clinical Cancer
Exercise Specialists (CES) ensured participant safety throughout both protocols. Five
different VO2peak values were compared using a repeated measures ANOVA: 1) VO2peak
obtained from the UNCCRI protocol, and 2) VO2peak values derived from four welldocumented 6MWT prediction equations.
University of Northern Colorado
Cancer Rehabilitation Institute
Treadmill Protocol
There are 21 total stages of the UNCCRI treadmill protocol, each stage lasting
one minute. Speed and/or grade was increased at the completion of each stage. Details
of the protocol appear in Table 1. Participants were informed that they would be
completing a UNCCRI Treadmill VO2peak protocol and could terminate the test at any
time, but were encouraged to continue to their maximum effort.
Before each test, participants were given the following instructions: 1) BP will be
taken every three minutes by a CES, 2) another CES will be recording HR and SpO2 and
changing speed and/or grade every minute, 3) a pulse oximeter will be placed on your
finger for the duration of the test to monitor oxygen saturation every minute, 4) a CES
will also stand behind you during the duration of the test for your safety and to ensure
proper placement on the treadmill belt, 5) we ask that you push yourself to maximum
exertion and although you may stop at any time, we would like you to reach the point
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where you feel that you can’t physically continue, 6) we recommend that you do not use
the handrails unless you feel it is absolutely necessary, 7) you must choose to use or not
use the handrails for the entire protocol, 8) after maximal exertion a cool down phase at a
lower speed and grade will be initiated until vitals reach near-resting measures.
The test ended when the participant reached his or her perceived maximum
exertion or could not continue further. The test concluded when the participant verbally
expressed when they had reached their maximum rate of perceived exertion (RPE) using
a modified Borg RPE, or when the participant physically grabbed onto the handrails to
signal the end of the test. Once the participant indicated they had reached maximum
effort, the cool down phase was initiated. When the participant’s vitals were close to
resting values and the participant indicated that they felt safe to get off the treadmill, the
treadmill was stopped. Final vitals were recorded, including when the maximum HR was
reached. The duration of the test until maximum exertion and the final completed stage
were also recorded.
The American College of Sports Medicine (ACSM) running and walking
equations were used to calculate VO2peak from the last completed stage of the protocol. If
the participant was walking at maximum exertion the following equation was used:
VO2peak (mL/kg/min) = (0.1 x S) + (1.8 x S x G) + 3.5. The variable S is the speed in
meters/min and G is the percent grade in decimal form. If the participant was running at
maximum exertion the following equation was used: VO2peak = (0.2 x S) + (0.9 x S x G)
+ 3.5. If the participant was using the handrails during the protocol the following
equation was used: VO2peak = 0.694 x [the ACSM walking/running value from above] +
3.33 (ACSM, 2013).
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Table 2
The University of Northern Colorado Cancer Rehabilitation Protocol
Stage

Speed Grade Time

0

1.0mph

0% 1 min

1

1.5mph

0% 1 min

2

2.0mph

0% 1 min

3

2.5mph

0% 1 min

4

2.5mph

2% 1 min

5

3.0mph

2% 1 min

6

3.3mph

3% 1 min

7

3.4mph

4% 1 min

8

3.5mph

5% 1 min

9

3.6mph

6% 1 min

10

3.7mph

7% 1 min

11

3.8mph

8% 1 min

12

3.9mph

9% 1 min

13

4.0mph 10% 1 min

14

4.1mph 11% 1 min

15

4.2mph 12% 1 min

16

4.3mph 13% 1 min

17

4.4mph 14% 1 min

18

4.5mph 15% 1 min

19

4.6mph 16% 1 min

20

4.7mph 17% 1 min

Cool- Down

**

0%

***
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The Six Minute Walk Test Protocol
The 6MWT was conducted under the guidelines of the American Thoracic
Society (ATS). The 6MWT took place in a 12.6-meter-long hallway at the UNCCRI.
Prior to the 6MWT, participants performed a pulmonary assessment using a MIR
Spirolab III® portable desktop spirometer to determine force vital capacity (FVC) and
forced expiratory capacity (FEV1) of the lungs. Two CES’s supervised the test to ensure
participant safety.
At the beginning of the test each participant was given the following instructions:
1) walk up and down the hallway for six minutes, reaching the colored dot at each end of
the hallway, 2) try to walk as far as possible in that six-minute time frame, and 3) at any
time you can stop to rest or sit in one of the chairs, but we ask that you keep walking as
soon as you feel able. The participants were asked to walk alone unless gait imbalances
required them to have a CES near to assist them. At every minute, participants were told
the time remaining and a standard verbal encouragement such as “Great job” was given.
One CES kept track of the time on a stopwatch and placed a mark on the data collection
sheet every time the participant completed one length of the hallway. At the end of the
test, participants were asked to stop where they were and a CES marked on the wall
where they had stopped. The CES measured the partial distance the participant had
covered from the end of the hallway to the spot on the wall with a meter stick. This
value was added to the total distance of lengths completed to ensure a precise
measurement of the distance covered. At the end of the test HR, BP, RPE and SpO2
values were recorded immediately by a CES.
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The distance and variables such as age, height, weight, FVC and FEV1 were used
to calculate predicted VO2peak from four well established prediction equations: 1) VO2peak
= 0.03 x distance (m) + 3.98 (Cahalin et al., 1996), 2) VO2peak = 0.02 x distance (m) –
0.191 x age (yrs) – 0.07 x weight (kg) + 0.09 x height (cm) + 0.26 x (RPP x 10^-3) +
2.45 (Cahalin et al., 1996), 3) VO2peak = 0.02 + distance (m) - 0.14 x age (yrs) - 0.07 x
weight (kg) + 0.03 x height (cm) + 0.23 x (RPP x 10^-3) + 0.10 x FEV1(L) – 1.19 x FVC
(L) + 7.77 (Cahalin et al., 1996), and 4) VO2peak = 4.948 + 0.023 x distance (m) (Ross et
al., 2010).
Statistical Analysis
A power analysis was conducted using the statistical program G-power (Version
3.1) prior to the study to determine the appropriate sample size for significance. For both
protocols a repeated measures ANOVA was utilized to examine the differences in
VO2peak obtained by the UNCCRI treadmill protocol against the VO2peak values
determined by the four 6MWT prediction equations. Paired t-tests were utilized to test
the differences in HR and SBP between the UNCCRI protocol and the 6MWT protocol.
A Pearson r-correlation between values obtained using the UNCCRI treadmill protocol
and 6MWT equations 1-4 were run to determine the strength of the relationship in
VO2peak. Significance was set to p < 0.05. All statistical analyses were conducted using
the Statistical Package for the Social Sciences software package (SPSS, Chicago, IL).
Results
Participant Characteristics
Table 3 displays the cancer types, and Table 4 displays age, height, weight, and
FVC/FEV1 for study participants. Table 5 displays all resting characteristics for
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participants prior to each test. The participants were comprised of 49 males and 79
females with a mean age of 62 ± 14 years, a mean height of 169 ± 8 cm, and a mean
weight of 78 ± 20 kg. Mean FVC was 3.44 ± 0.89 L and mean FEV1 was 2.59 ± 0.72 L.
Mean resting heart rate (RHR), systolic blood pressure (RSBP), and diastolic blood
pressure (RDBP) before the UNCCRI treadmill test were 82 ± 14 bpm, 125 ± 15 mmHg
and 75 ± 9 mmHg, respectively. The mean RHR, RSBP, and RDBP before the 6MWT
was 78 ± 14 bpm, 123 ± 13 mmHg and 74 ± 8 mmHg, respectively. There was a
significant difference observed between RHR before the treadmill and before the 6MWT
(p = 0.003). There was no significant difference observed in RSBP (p = 0.137) and in
RDPB (p = 0.419) prior to each test. Twenty four percent of the CS were undergoing
chemotherapy and/or radiation treatments during testing. All participants completed each
of the VO2peak protocols without complications.
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Table 3
Cancer Types
Cancer Type
Breast
Prostate
Lymphoma/Leukemia
Colon
Lung
Skin
Ovarian
Renal
Uterine
Sarcoma
Pancreatic
Esophageal
Multiple Myeloma
Rectal
Thyroid
Ampullary
Oroparyngeal
Stomach
Neuroendocrine

N
51
19
12
12
7
6
5
5
3
3
3
2
2
2
1
1
1
1
1

Table 4
Age, Weight, Height, FVC, FEV1
Age
62 ± 14
Weight (kg)
78 ± 20
Height (cm)
169 ± 8
FVC (L)
3.44 ± 0.89
FEV1 (L)
2.59 ± 0.72
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Table 5
Resting Characteristics
UNCCRI TM

6MWT

P-value

RHR (bpm)

82 ± 14

78 ± 14

0.003*

RSBP (mmHg)

125 ± 15

123 ± 13

0.137

RDBP (mmHg)

75 ± 9

74 ± 8

0.419

Note: RHR = resting heart rate; RSBP = resting systolic blood pressure; RDBP = resting
diastolic blood pressure; *denotes a p-value < 0.05.

Table 6
Mean Peak Exercise Values
UNCCRI TM
HR (bpm)
150 ± 21
SBP (mmHg)
150 ± 18
DBP (mmHg)
77 ± 10
RPE
9±2
SO2 (%)
94 ± 3
TM Time (min)
10.5 ± 2.9
Walk Distance (m)
-

6MWT
109 ± 21
139 ± 20
75 ± 9
6±2
95 ± 3
499 ± 101

P-Value
<0.001*
<0.001*
0.013*
<0.001*
<0.001*
-

Note: HR = heart rate; SBP = systolic blood pressure; DBP = diastolic blood pressure;
RPE = rate of perceived exertion; *denotes significant differences between groups.

Validity of Predicted VO2peak for the 6MWT
Table 6 summarizes predicted peak oxygen consumption values of the UNCCRI
treadmill test and the 6MWT. Average time spent on the treadmill was 10.5 ± 2.9
minutes and the average distance walked during the 6MWT was 499 ± 101 meters (m).
6MWT peak HR (109 ± 21 bpm), SBP (139 ± 20 mmHg), DPB (75 ± 9 mmHg), and
RPE (6 ± 2) were significantly lower (p < 0.05) compared to the UNCCRI treadmill
protocol peak HR (150 ± 21 bpm), SBP (150 ± 18 mmHg), DPB (77 ± 10 mmHg), and
RPE (9 ± 2). Oxygen saturation during the 6MWT was significantly higher (95 ± 3) than
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the UNCCRI protocol (94 ± 3) (p < 0.001). The UNCCRI protocol yielded a
significantly higher VO2peak of 24.7 ± 7.4 mL/kg/min compared to all four 6MWT
prediction equations (p<0.001). Figure 1 displays the mean VO2peak values for the
UNCCRI treadmill protocol and all four 6MWT prediction equations. Equations 1, 2, 3
and 4 yielded VO2peak values of 18.9 ± 3.0, 14.2 ± 4.6, 8.3 ± 3.8, and 16.4 ± 2.3
mL/kg/min, respectively.
Correlation Analyses
Figures 2-5 display correlations between the UNCCRI treadmill protocol and all
four VO2peak prediction equations. Positive strong correlations occurred between the
UNCCRI treadmill protocol and 6MWT prediction equation 1 (r = 0.83) and equation 4
(r = 0.83). Moderately strong correlations occurred between the UNCCRI treadmill
protocol and 6MWT equation 2 (r = 0.74) and equation 3 (r = 0.70).

Mean VO2peak
VO2peak mL/kg/min

30
25
20

24.7

*
18.9

15

14.2

10

*

*

16.4

*
8.3

5
0
UNCCRI TM

Equation 1

Equation 2

Equation 3

Equation 4

Prediction Equation

Figure 1. Mean VO2peak values. * denotes a significant difference (p < 0.001) between
the 6MWT prediction equation and the UNCCRI treadmill VO2peak value.
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Figure 2. Correlation between UNCCRI Treadmill VO2peak and 6MWT prediction
Equation 1 VO2peak.
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Figure 3. Correlation between UNCCRI Treadmill VO2peak and 6MWT prediction
Equation 2 VO2peak.
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Figure 4. Correlation between UNCCRI Treadmill VO2peak and 6MWT prediction
Equation 3 VO2peak.
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Figure 5. Correlation between UNCCRI Treadmill VO2peak and 6MWT prediction
Equation 4 VO2peak.
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Discussion
The aim of this study was to assess the validity of predicted VO2peak from the
6MWT compared to the UNCCRI treadmill protocol in a cancer specific population. It
was hypothesized that VO2peak predicted from the 6MWT equations would be
significantly lower than VO2peak obtained from the UNCCRI treadmill protocol. This
was confirmed with the UNCCRI protocol yielding significantly higher VO2peak values (p
< 0.001) compared to all four 6MWT prediction values. Other studies have cautioned
using 6MWT VO2peak prediction equations in populations where individual monitoring is
crucial due to the variability in VO2peak values (Maldonado-Martin et al., 2006; Ross et
al., 2010). Although Equation 1 was found to have a strong correlation with the
UNCCRI protocol (r = 0.83), the differences between VO2peak values were significant (p
< 0.001), concluding that this trend isn’t representative of validity. Maldonado-Martin et
al. (2006) investigated Equation 1 and questioned the validity of using the walk test to
determine functional capacity in elderly patients with heart failure (HF). In their study,
the measured VO2peak was 13.5 ± 2.9 (mL/kg/min) while the prediction equation using
6MWT distance significantly overestimated VO2peak (17.2 ± 3.3; p < 0.05). The
researchers concluded that predicting VO2peak results in substantial variability and should
not be used in HF patients where an accurate determination of functional capacity is
essential. Ross et al. (2010) reviewed several studies and determined an equation to
predict VO2peak from 1083 patients with diverse cardiopulmonary disease diagnoses.
Although a moderate correlation (r=0.59) was found between distance covered and
predicted VO2peak, the standard estimation of error (SEE) was unacceptably large (3.82
mL/kg/min) for clinical usefulness in individual patients. They state that their prediction
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equation, like other prediction equations, is of limited usefulness for individual patients.
Like other disease populations, validity of functional capacity is imperative in CS.
Moderate to strong correlations were seen between the UNCCRI VO2peak value
and 6MWT VO2peak values from Equation 1 (r = 0.83) and Equation 3 (r = 0.70). The
correlations, although strong, do not validate the 6MWT because significant differences
(p < 0.001) were observed between the UNCCRI protocol and Equations 1-4. Several
studies found similar positive correlations between VO2peak measured during a CPET
compared to VO2peak during the 6MWT (Cahalin et al., 1996; Faggiano et al., 1997;
Guazzi et al., 2009; Jehn et al., 2009; Zugck et al., 2000). In 37 patients with varying
classifications of heart failure, a good positive correlation (r = 0.72) was overall seen
between the 6MWT VO2peak and from a CPET VO2peak (Jehn et al., 2009). However,
when these patients were grouped according to their VO2peak, the correlation was highly
dependent on the functional impairment of the subjects. In subjects with a VO2peak
greater than 25.2 mL/kg/min, the 6MWT VO2peak was significantly lower than the CPET
test (23.4 ± 2.6 vs. 27.6 ± 3.3). On the other hand, those with a VO2peak equal to or lower
than 17.5 mL/kg/min, the 6MWT VO2peak was significantly higher than the CPET test
(15.5 ± 3.6 vs. 13.6 ± 2.5). It has been suggested that these data should be taken into
careful consideration when using the 6MWT to evaluate clinical prognosis in patients
with varying degrees of clinical disability (Jehn et al., 2009).
Other studies have reported similar results that at higher levels of functional
capacity the 6MWT should not be used as a measure of VO2peak (Deboeck et al., 2014;
Fujino et al., 2015; Lipkin et al., 1986). Lipkin et al. (1986) found that maximal CPET
tests may be more appropriate for patients who have mild HF, or a VO2 of greater than
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20 mL/kg/min. On average, the CS in the current study had a VO2peak over this threshold
and it is concluded that a maximal CPET is more appropriate in CS. Even for the CS
under this threshold, a maximum CPET was found to be more appropriate than the
6MWT. Deboeck et al. (2014) stated that a distance greater than 500m during the
6MWT results in the test becoming less sensitive to increases in VO2peak. The average
distance walked for our CS was 499m, which implies that one should be careful to
interpret 6MWT VO2peak as valid. Fujino et al. (2015) found a significant correlation in
VO2peak (r = 0.55, p < 0.01) for distances below 450m, but no correlation with distances
greater than 450m (r = 0.304, p = 0.193). Several other studies report that there is not a
significant correlation between the 6MWT VO2peak and a CPET VO2peak in healthy and
elderly populations who have higher degrees of functional capacity compared to chronic
disease populations (Deboeck et al., 2014; Green et al., 2001; Gremeaux et al., 2008). In
healthy individuals, and those who may have early stage clinical disease or relatively
high functional capacity, the 6MWT may not be suitable for evaluating exercise capacity
(Jones, Eves, Haykowsky, Joy, & Douglas, 2008; Schmidt et al., 2013). The American
Thoracic Society states that although investigators have used the 6MWT in clinical
settings, this does not prove that the test is clinically useful or the best test for
determining functional capacity (American Thoracic Society, 2002). The 6MWT itself
can only estimate VO2peak, and the information provided by the 6MWT should be
considered complimentary to CPET but not a replacement for it.
All participants were able to safely complete both protocols with no significant
adverse events. In CS, the 6MWT produced significantly lower heart rate values than the
UNCCRI treadmill protocol (109 ± 21 bpm vs. 150 ± 21 bpm, respectively). This
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supports the conclusion that the 6MWT in a cancer specific population is a submaximal
protocol and should not be used to assess VO2peak. Other studies have demonstrated
similar results with significant differences in heart rate values between the walk test and a
CPET test for several disease and healthy populations (Blanco et al., 2010; Cavalheri et
al., 2016; Deboeck et al., 2014; Green et al., 2001; Gremeaux et al., 2008; Zugck et al.,
2000). Contrary to these results, other researchers found that the walk test elicited a
maximal exercise response in participants with a low VO2peak, questioning the test as a
submaximal protocol in other disease populations (Faggiano et al., 1997; Jehn et al.,
2009). Faggiano et al. (1997) found the walk test to be questionable as a submaximal test
in HF populations because 73% of subjects were above anaerobic threshold at
termination. Lower HR values during the 6MWT are likely seen because the participant
sets their own pace. It was uncommon to find CS putting in maximum effort, even when
the stated goal of the test is to walk as far as possible in that time frame. This was also
demonstrated by the results of the RPE for participants. For the UNCCRI treadmill
protocol the RPE averaged 9 ± 2 and the walk test only averaged 6 ± 2 on a scale of 0-10.
The treadmill requires participants to undergo increased intensities until they reach their
maximum effort, while the 6MWT is purely subjective. The test is self-paced and
motivation is a large factor that can account for up to 30% of the variability (Enright,
2003). Although some CS may prefer a submaximal test because of treatment-related
side effects, a treadmill protocol may be necessary to help factor out motivation levels.
The significant difference seen between RHR before the treadmill and before the walk
test is likely due to the CS being apprehensive about a treadmill test.
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It was hypothesized that the multivariate prediction equations taking into account
individual differences in height, weight and other physiologic variables would have a
higher correlation with the UNCCRI treadmill protocol. The correlation found between
Equation 3 and the UNCCRI protocol was actually lower (r = 0.70) compared to
Equation 1 and the UNCCRI protocol (r = 0.83). Equation 3 had a lower correlation with
the UNCCRI protocol most likely due to this equation being derived from a cardiac, not
cancer specific, population. These results demonstrate that these specific equations
cannot be used to accurately assess VO2peak in a cancer specific population.
Limitations and Future Directions
There were several limitations to this study. First, the hallway distance at the
UNCCRI was only 12.6 meters and a longer hallway may have increased final distance
due to the participants not having to turn around as often (Beekman et al., 2013).
However, course length has been shown to not significantly affect the results of the
6MWT with courses greater than 15 meters (Sciurba et al., 2003; Weiss, 2000). Second,
gas analysis was not utilized in either test to confirm VO2peak results, although the
UNCCRI protocol has been validated in a prior study using gas analysis (r = 0.93)
(Shackelford et al., 2015). Third, CS already enrolled at the UNCCRI have previously
undergone UNCCRI treadmill assessments and the familiarity with the protocol
compared to the 6MWT could allow them to perform at a higher level. Last, motivation
levels could have been affected by the CES assisting with the protocols if the participant
was already enrolled at the UNCCRI and had been familiar with them and their training
style. For future research, a longer track and gas analysis during both protocols might be
suggested to strengthen statistical significance and validity. Future studies might also
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provide the necessary data for equations to be developed that could more accurately
assess VO2peak from the 6MWT in CS. Although a small portion of this study, those
participants who utilized the handrails during the treadmill protocol had less significant
differences in VO2peak during the treadmill and 6MWT prediction Equation 1. This trend
should be further investigated to see if the 6MWT is more accurate in CS who have to
utilize the handrails during a treadmill assessment.
Conclusion
This study assessed the validity of predicting VO2peak from the 6MWT compared
to the UNCCRI treadmill protocol in a cancer specific population. Findings suggest that
the 6MWT is not a valid test for predicting VO2peak in CS due to the fact that all four
6MWT prediction equations significantly underestimated VO2peak in CS. Our results
demonstrate that CS can safely complete maximal protocols for the best VO2peak value.
Other studies have concluded that cancer survivors can safely complete peak
cardiopulmonary exercise testing (De Backer et al., 2007; Jones et al., 2007; Kilka et al.,
2009; May et al., 2010). Even those CS with limited functional capacity who needed to
utilize the handrails could do so with accurate results. The 6MWT may be favored
because of the limited exercise capacity often seen in CS, but shouldn’t be substituted as
an assessment tool in CS for VO2peak. The completion of a maximal assessment provides
more precise results that lead to more accurate prescription intensities to progress
exercise capacity safely over the course of rehabilitation. It is proposed that cancer
rehabilitation clinics do not use the 6MWT to evaluate VO2peak, and to instead use the
UNCCRI treadmill protocol to obtain VO2peak.
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APPENDIX A
INFORMED CONSENT FOR PARTICIPATION
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APPENDIX B
INSTITUTIONAL REVIEW BOARD
APPROVAL
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APPENDIX C
UNIVERSITY OF NORTHERN COLORADO
CANCER REHABILITATION INSTITUTE
TREADMILL PROTOCOL
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Client Name: _____________________________
Date:__________________________

Client ID #:_________________

Prior to testing take resting HR, BP, and Weight
Date of Birth:_________________
Est. HR Max: _____
Body Weight (lbs):)_________
assessment/reassessment? Y N

Age: ________ Phase: __________ RHR: ___________ RBP: __________

Kg (lbs/2.2:) ________ Is this the same data acquired from an initial

RMCRI Cancer Treadmill Protocol Worksheet
Stage

Speed

Grade Time

0

1.0mph

0%

1

1.5mph

0%

*

2

2.0mph

0%

*

3

2.5mph

0%

*

4

2.5mph

2%

*

5

3.0mph

2%

*

6

3.3mph

3%

*

7

3.4mph

4%

*

8

3.5mph

5%

*

9

3.6mph

6%

*

10

3.7mph

7%

*

11

3.8mph

8%

*

12

3.9mph

*

13

4.0mph

9%
10%

14

4.1mph

11%

*

15

4.2mph

12%

*

16

4.3mph

13%

*

17

4.4mph

14%

*

18

4.5mph

15%

*

19

4.6mph

16%

*

20
CoolDown

4.7mph
**

17%

*

0%

1 min

*

*

BP

HR

RPE

SpO2
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*Identify time for each the final stage and for the cooldown.
**Identify speed for cool-down.
Note: If client changes from a walk to a run during this test, identify the time when
the gait changed.
Was the client holding the handrails?
Yes No
Was the client running during the last stage completed?
what time did running start: _____________

Yes No

If Yes,

VO2 Peak (L/Min) : ____________ VO2 Peak (mL/kg/min) : _____________
Peak RER: ________ Max HR:__________
FINAL TIME to peak/volitional fatigue: _____________________ as a decimal
(minutes . (sec/60))___________________
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APPENDIX D
SIX MINUTE WALK TEST PROTOCOL
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Six Minute Walk Test Data Collection
Client Name: ________________________

Client ID #:______________ Date:

_________
Date of Birth: ______________

Age: ______

Phase:

_____
RHR: __________

RPB: __________

Est. HR Max:

_________
Body Weight (lbs):_________ Body Weight (kg):___________ Height (ft.,
in.)____________
FEV1 (L):___________

FVC (L):____________ Height (cm):____________

Equipment needed for test: two stethoscopes
monitor
sticky notes
measuring stick
stopwatch
Place a mark for
every length of the
hallway completed

two BP cuffs

pulse ox

HR

two portable chairs

Total number of hall lengths walked: _________________
Partial length distance: ______________________(ft, in.)
After Completion of the Test:
HR:________ BP:_________ RPE:_________ SPO2 ________________
Conversions:

1in = 2.54 cm
1 meter = 3.28 feet

12 in = 1 foot
1m = 100cm
39.37 inches = 1 meter RPP= SBP x HR

Hallway Distance: 1 length = 12.6 meters
Total Lengths Walked: ______________ * 12.6 = ________________ meters
Partial Length Distance: ___________ (ft, in.) = ____________ inches = ___________
meters
Total Distance Walked (m) = (# of lengths*12.6m) + partial distance (m)
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_____________ total lengths walked (m) + ______________ partial distance (m) =

Total Distance Walked (m) = _________________

Cahalin Equation 1:
Peak VO2 = 0.03 x distance (m) + 3.98
Peak VO2 = 0.03 x _________ (m) + 3.98
Peak VO2 (mL/kg/min):_____________

Cahalin Equation 2:
Peak VO2=0.02 x distance(m) – 0.191 x age(yr) – 0.07 x weight(kg) + 0.09 x
height(cm) + 0.26 x RPP x 10-3 + 2.45
Peak VO2=0.02 x ________ (m) – 0.191 x _____ (yr) – 0.07 x ______ (kg) + 0.09 x
_______(cm) + 0.26 x _________(RPP) x 10-3 + 2.45
Peak VO2 (mL/kg/min):_____________

Cahalin Equation 3:
Peak VO2=0.02 x distance(m) - 0.14 x age(yr) – 0.07 x weight(kg) + 0.03 x height(cm)
+ 0.23 x RPP x 10-3 + 0.10 x FEV1 (L) – 1.19 x FVC (L) + 7.77
Peak VO2=0.02 x ________(m) - 0.14 x _______(yr) – 0.07 x _______(kg) + 0.03 x
_______(cm) + 0.23 x ___________(RPP) x 10-3 + 0.10 x ______ (L) – 1.19 x
_______(L) + 7.77
Peak VO2 (mL/kg/min):______________

Ross Equation:
Mean Peak VO2 = 4.948 + 0.023 * mean 6MWD (meters)
Mean Peak VO2 = 4.948 + 0.023 * __________ (m)
Peak VO2 (mL/kg/min):______________
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APPENDIX E
ABBREVIATIONS
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ACSM – American College of Sports Medicine
ATS – American Thoracic Society
BP – Blood Pressure
CAD – Coronary Artery Disease
CES – Cancer Exercise Specialist
COPD – Chronic Obstructive Pulmonary Disease
CPET – Cardiopulmonary Exercise Testing
CRF – Cardiorespiratory Fitness
CS – Cancer Survivor
DBP – Diastolic Blood Pressure
FEV1 – Forced Expiratory Capacity
FVC – Forced Vital Capacity
HF – Heart Failure
HR – Heart Rate
NCSLC – Nonsmall Cell Lung Cancer
RDBP – Resting Diastolic Blood Pressure
RER – Respiratory Exchange Ratio
RHR – Resting Heart Rate
RPE – Rate of Perceived Exertion
RPP – Rate Pressure Product
RSBP – Resting Systolic Blood Pressure
SBP – Systolic Blood Pressure
SEE – Standard Error of Estimation
SPO2 – Blood Oxygen Saturation
UNCCRI – University of Northern Colorado Cancer Rehabilitation Institute
US – United States
VO2max – Maximum Volume of Oxygen Consumption
VO2peak – Peak Volume of Oxygen Consumption
6MWT – Six Minute Walk Test

